Last €207.96 EUR
Change Today -0.09 / -0.04%
Volume 1.1K
As of 1:54 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-br (RHO) Snapshot

Open
€207.20
Previous Close
€208.05
Day High
€208.91
Day Low
€206.50
52 Week High
02/27/14 - €224.04
52 Week Low
06/25/13 - €172.80
Market Cap
180.0B
Average Volume 10 Days
3.7K
EPS TTM
--
Shares Outstanding
160.0M
EX-Date
03/6/14
P/E TM
--
Dividend
€7.80
Dividend Yield
3.07%
Current Stock Chart for ROCHE HOLDING AG-BR (RHO)

roche holding ag-br (RHO) Related Bloomberg News

View More Bloomberg News

roche holding ag-br (RHO) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-br (RHO) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-br (RHO) Key Developments

Roche Holding AG Reports Sales Results for the First Quarter of 2014

Roche Holding AG reported sales results for the first quarter of 2014. For the quarter, the company's sales dipped by 1% year on year to CHF 11.5 billion ($13.1 billion) in the first quarter of this year. On a constant exchange rates basis, the company's sales were up by 5%.

Roche Enters into Oncology Research Collaboration with Oryzon Genomics

Roche has entered into a global research, development, and commercialisation collaboration with Oryzon Genomics for the latter's inhibitors of lysine specific demethylase-1 (LSD1/KDM1A). As per the agreement, Roche gains the responsibility for developing and commercialising Oryzon's lead agent, ORY-1001, which is in the process of undergoing Phase I/IIA development for acute myeloid leukaemia (AML), as well as/or its backup compounds. Roche will also be licensing two patent families created by Oryzon as part of its research in LSD1, with the Roche also having the option to include other programmes. Furthermore, the companies will undertake collaborative research programme that will initially span two years in order to 'better understand the potential of LSD1 inhibitors in oncology and haematology. The collaboration will be between Oryzon and Roche's New York-based Translational and Clinical Research Centre (TCRC). In turn, Oryzon will receive upfront and near-term milestone payments amounting to USD 21 million. It would also be eligible for over USD 500 million-worth of development, commercialisation, and sales milestone payments, and up to double-digit royalties on sales.

Roche Holding AG to Report Q1, 2014 Sales/Trading Statement Results on Apr 15, 2014

Roche Holding AG announced that they will report Q1, 2014 sales/trading statement results on Apr 15, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHO:GR €207.96 EUR -0.09

RHO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,559 GBp -4.50
Merck & Co Inc $56.57 USD +0.31
Novartis AG SFr.74.70 CHF +0.35
Pfizer Inc $30.37 USD +0.275
Sanofi €75.48 EUR +0.71
View Industry Companies
 

Industry Analysis

RHO

Industry Average

Valuation RHO Industry Range
Price/Earnings 19.9x
Price/Sales 4.5x
Price/Book 11.3x
Price/Cash Flow 16.2x
TEV/Sales 3.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-BR, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.